一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括Capmatinib；Amivantamab，当前状态为研究进行中，已停止招募。登记地点显示中国北京、成都、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Capmatinib；Amivantamab · I 期 / II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出4项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Sichuan Cancer Hospital · 成都
- West China Hospital Sichuan University · 成都
- Chongqing University Cancer Hospital · 重庆
- The First Affiliated Hospital Sun Yat sen University · 广州
- Second Affiliated Hospital, School of Medicine, Zhejiang University · 杭州
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine · 杭州
- Huizhou Municipal Central Hospital · 惠州
- Fudan University Shanghai Cancer Center · 上海
- Shanghai Pulmonary Hospital · 上海
- Shengjing Hospital Of China Medical University · 沈阳
- The First Affiliated Hospital of Xian Jiaotong University · 西安
- Yantai Yuhuangding Hospital · 烟台
- Henan Cancer Hospital · 郑州
公开的入选条件
- * Previously diagnosed with histologically or cytologically confirmed unresectable Stage IV (metastatic) non-small cell lung cancer (NSCLC) (any histology)
- * May have: definitively, locally treated brain metastases that are clinically stable and asymptomatic for greater than (\>) 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \[\<=\]10 milligrams (mg) prednisone or e
- * May have a prior malignancy (other than the disease under study) the natural history or treatment of which is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- * A participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05488314；登记信息更新于 2026-09-25。